BCIDP Infectious Disease: The Antibiotic Stewardship Masterclass, How to Pass the BPS ID Board Exam in 2026

BCIDP Infectious Disease: The Antibiotic Stewardship Masterclass, How to Pass the BPS ID Board Exam in 2026

by

Infectious diseases pharmacy is a craft. The best ID pharmacists blend clinical judgment, microbiology, and stewardship in every decision. The BCIDP exam tests for that craft. This guide shows you how to build it—with the antibiotic stewardship playbook at the center—and how to pass the BPS Infectious Diseases Pharmacy (BCIDP) exam in 2026. You will get concrete frameworks, high-yield facts, study plans, and realistic cases. No hype. Just what works.

What the BCIDP exam really tests

The exam is not about memorizing bug–drug lists. It checks whether you can protect patients and a hospital’s microbiome at the same time. That means you must:

  • Choose smart empiric therapy based on host, source, severity, and local data. Why: early appropriate therapy saves lives.
  • Use diagnostics wisely to stop, narrow, or switch therapy. Why: diagnostic stewardship prevents both undertreatment and overuse.
  • Optimize PK/PD at the bedside. Why: dosing is therapy.
  • Prevent resistance through durations, IV-to-PO, and de-escalation. Why: less exposure equals less selection pressure.
  • Communicate and lead within an Antimicrobial Stewardship Program (ASP). Why: change happens through people, not only orders.

Exam basics for 2026

Expect a comprehensive, scenario-heavy exam. As of recent cycles, BPS uses multiple-choice questions with patient cases. Many items feel like “What’s your next best step?” or “Which choice aligns with stewardship and outcomes?” Assume unscored pretest items are mixed in, and time yourself accordingly. Eligibility, number of questions, and timing can change; review the current BPS bulletin when you apply. Build your plan around when you will test in Spring or Fall windows.

Antibiotic stewardship masterclass: the core moves you must own

Stewardship is your anchor. Master these and you’ll answer a third of the exam more confidently.

  • The four moments of antibiotic decision-making
    • Moment 1: Does the patient need antibiotics right now? Check source, severity, and risk for resistant organisms.
    • Moment 2: If yes, what spectrum and dose? Use local antibiogram, patient factors, and PK/PD targets.
    • Moment 3 (48–72h): Can you stop, narrow, or switch to oral? Use cultures, PCR panels, biomarkers, and clinical trajectory.
    • Moment 4: What is the shortest effective duration? Match to source control and evidence.
  • Diagnostic stewardship
    • Order tests that change management. Avoid “pan-culturing.”
    • Interpret rapid diagnostics with pretest probability. A positive PCR gene (e.g., mecA) requires clinical context.
    • Use procalcitonin to support de-escalation in lower respiratory infections, not as a stand-alone decision-maker.
  • IV-to-PO switch
    • Candidates: stabilized vitals, functioning GI tract, source controlled, oral bioavailability adequate (e.g., fluoroquinolones, linezolid, doxycycline, TMP-SMX).
    • Why: shortens length of stay, lowers cost and line risks, no loss in efficacy when criteria met.
  • De-escalation and targeted therapy
    • De-escalate from broad empiric (e.g., piperacillin-tazobactam + vancomycin) to pathogen-directed therapy once cultures result.
    • For ESBL bacteremia, prefer a carbapenem; avoid piperacillin-tazobactam in serious infections.
  • Right durations (assumes source control and clinical response)
    • CAP: ~5 days.
    • HAP/VAP: ~7 days.
    • Uncomplicated gram-negative bacteremia: ~7 days.
    • Cellulitis (nonpurulent): ~5 days.
    • Pyelonephritis: ~7 days (agent-dependent).
    • Endocarditis: often 4–6 weeks (organism/valve specific).
    • Complicated intra-abdominal infection: 4–7 days after control.
  • Formulary and “handshake” stewardship
    • Prospective audit with feedback outperforms hard restriction for culture and relationships.
    • Use preauthorization for highest-risk drugs (e.g., ceftazidime-avibactam, cefiderocol) with rapid follow-up to avoid delays.
  • Beta-lactam allergy de-labeling
    • Most “penicillin allergies” are not true IgE-mediated. Use history, test dosing, or skin testing protocols when appropriate.
    • Why: it improves outcomes and reduces C. difficile and resistance pressure.

PK/PD and dosing that win cases

On test day, you will be rewarded for dosing mastery.

  • PK/PD targets
    • Beta-lactams: time above MIC (fT>MIC). Use extended infusions for severe infections or high MICs.
    • Aminoglycosides: Cmax:MIC. Use once-daily high-dose in most systemic infections (not synergy dosing in endocarditis).
    • Fluoroquinolones: AUC:MIC. Levofloxacin high-dose (750 mg) short course achieves targets in pneumonia.
    • Vancomycin: AUC/MIC ~400–600 (assuming MIC 1). Switch from trough-only to AUC-based monitoring when feasible.
  • Loading doses and critical illness
    • Give loading doses for vancomycin and some beta-lactams in septic shock to reach therapeutic levels quickly.
    • Augmented renal clearance can drop levels; adjust dosing upward or use extended infusions.
  • Renal replacement, ECMO, and obesity
    • CRRT often requires higher or more frequent dosing than intermittent hemodialysis.
    • ECMO can increase volume of distribution for lipophilic drugs; monitor levels when possible.
    • In obesity, consider actual vs adjusted body weight per drug, and use loading doses thoughtfully.
  • Therapeutic drug monitoring
    • Vancomycin AUC-guided dosing lowers nephrotoxicity and maintains efficacy.
    • Aminoglycoside levels confirm peak and trough goals; synergy dosing in endocarditis uses lower peaks.

Microbiology and resistance you must recall under pressure

  • Match the bug
    • Gram-positives: MRSA (mecA), VRE (vanA/B), penicillin-resistant pneumococcus.
    • Gram-negatives: Pseudomonas, Acinetobacter, ESBL/AmpC Enterobacterales, CRE (KPC, NDM, OXA-48-like).
    • Anaerobes: Bacteroides fragilis group (resistant to clindamycin), Clostridioides difficile.
    • Atypicals: Mycoplasma, Chlamydia, Legionella (no beta-lactams).
  • Resistance mechanisms
    • ESBL: hydrolyze most penicillins/cephalosporins. Carbapenems are reliable; cefepime is unreliable in bacteremia.
    • AmpC: inducible in organisms like Enterobacter cloacae complex. Avoid third-generation cephalosporins; cefepime or carbapenems are better.
    • CRE: choose agents based on carbapenemase—KPC (ceftazidime-avibactam, meropenem-vaborbactam), MBL (cefiderocol; may combine with aztreonam-based strategies).
    • MRSA: daptomycin is inactive in pneumonia; linezolid covers lungs well; ceftaroline has MRSA activity.
  • Susceptibility testing pearls
    • MICs are not linear with outcomes; use breakpoints and site/pharmacology.
    • “Susceptible, dose-dependent” means efficacy requires higher dosing or infusion strategies.
    • D-test: detects inducible clindamycin resistance in staphylococci.
    • Breakpoints evolve; stewardship must adapt with them.

High-yield therapeutic blueprints

  • Pneumonia
    • CAP inpatient non-severe: beta-lactam + macrolide or a respiratory fluoroquinolone. Duration ~5 days if stable.
    • Severe CAP with MRSA risk: add linezolid (lung penetration) or vancomycin.
    • HAP/VAP: cover Pseudomonas; add MRSA coverage per risk. De-escalate at 48–72h; ~7 days total if improving.
  • Bloodstream infection
    • Staph aureus bacteremia: repeat blood cultures, evaluate for endocarditis. Treat MRSA with vancomycin or daptomycin; avoid linezolid for bacteremia.
    • Gram-negative bacteremia (uncomplicated): ~7 days; oral step-down possible with active high-bioavailability agents and stability.
  • Endocarditis
    • Native valve MSSA: nafcillin/oxacillin or cefazolin.
    • MRSA: vancomycin or daptomycin (high dose). Consider synergy in enterococcal disease (ampicillin + ceftriaxone).
  • Skin and soft tissue
    • Nonpurulent cellulitis: target streptococci; 5 days often enough.
    • Purulent infections: include MRSA coverage; incision and drainage first.
  • CNS infections
    • Meningitis empiric adult: vancomycin + ceftriaxone (add ampicillin if Listeria risk). Use high-dose, ensure CSF penetration.
  • Intra-abdominal infections
    • Source control is therapy. Choose coverage for gram-negatives and anaerobes; 4–7 days after control.
  • UTI
    • Cystitis: nitrofurantoin or fosfomycin when appropriate; avoid nitrofurantoin in pyelonephritis.
    • Pyelonephritis: fluoroquinolone (if active) or IV beta-lactam; ~7 days common with effective agents.
  • Bone and joint
    • Long durations (often 6 weeks) and source control. Consider MRSA agents as needed; rifampin for prosthetic joint after bacteremia clears.
  • C. difficile infection
    • First-line: fidaxomicin when available; oral vancomycin acceptable. Add bezlotoxumab for high recurrence risk.
    • Stop unnecessary antibiotics and acid suppressants where possible.
  • Special populations
    • Neutropenic fever: cover Pseudomonas promptly; add antifungals if persistent fever and instability.
    • Pregnancy: avoid tetracyclines and fluoroquinolones; time TMP-SMX carefully; beta-lactams are mainstays.
    • Hemodialysis/CRRT: know post-dialysis dosing and CRRT adjustments.

Stewardship metrics, policy, and quality

  • Metrics
    • Days of therapy (DOT) per 1,000 patient-days.
    • Antibiotic utilization by class and unit; watch broad-spectrum “days.”
    • C. difficile rates, MRSA rates, resistance trends.
    • Process measures: IV-to-PO conversion rates, time to de-escalation, adherence to guidelines.
  • Core elements and accreditation
    • Physician and pharmacist leadership, accountability, action, tracking, reporting, and education.
    • Policies that support, not punish: preauthorization with rapid approvals; audit with face-to-face feedback.
  • Financial stewardship
    • Shorter durations and oral switches reduce length of stay and drug spend without harming outcomes.
    • Reserve novel agents for documented need; this protects future activity and budget.

Study plan: 16 weeks to peak

Four months is enough if you focus. Use a daily 60–90 minute block plus one longer weekly session.

  • Weeks 1–2: Foundations
    • Micro review: Gram stain, anaerobes, atypicals, fungi; resistance mechanisms.
    • PK/PD principles; renal/hepatic dosing; therapeutic drug monitoring.
  • Weeks 3–6: Syndromes and stewardship
    • Respiratory, bloodstream, endocarditis, CNS, skin/soft tissue.
    • Stewardship core moves; diagnostic stewardship; durations; IV-to-PO.
  • Weeks 7–10: Complex care
    • Intra-abdominal, UTI, bone/joint, C. difficile.
    • Immunocompromised hosts, OPAT, pregnancy, dialysis/CRRT, obesity, ECMO.
  • Weeks 11–13: Newer agents and resistance
    • CRE, DTR Pseudomonas, ESBL/AmpC; matching novel beta-lactam/beta-lactamase inhibitors.
    • Allergy delabeling, SDD concept, breakpoint updates.
  • Weeks 14–15: Full-length practice
    • Two timed exams. Review every miss and near-miss.
    • Build a one-page “durations and switch” sheet and a one-page “bug–drug” sheet from memory.
  • Week 16: Polish
    • Rehearse calculations (CrCl, dosing intervals), vancomycin AUC logic, aminoglycoside dosing.
    • Light review of guidelines and algorithms; sleep well.

Practice cases and how to think

Case 1: A 68-year-old with septic shock from likely intra-abdominal source after perforated diverticulitis. Creatinine clearance 150 mL/min (augmented). Blood cultures pending.

  • Best empiric beta-lactam strategy? Choose a broad agent with extended infusion (e.g., piperacillin-tazobactam or meropenem) plus MRSA coverage only if risk. Why: augmented clearance risks subtherapeutic levels; extended infusion improves fT>MIC.
  • Duration? 4–7 days after source control and stability. Why: longer courses do not improve outcomes and increase harms.

Case 2: ESBL E. coli bacteremia from pyelonephritis. Patient stable after 48 hours.

  • Targeted therapy? A carbapenem for definitive therapy. Why: ESBL bacteremia has higher failure with piperacillin-tazobactam.
  • Oral step-down? Consider if susceptible to high-bioavailability agents (e.g., TMP-SMX, fluoroquinolone) and patient is stable. Why: oral therapy can complete a ~7-day course safely.

Case 3: MRSA pneumonia, creatinine clearance 40 mL/min, platelets 90,000.

  • Choice: vancomycin vs linezolid? Linezolid has superior lung penetration and avoids vancomycin nephrotoxicity risk but watch myelosuppression. If platelets are trending down, vancomycin with careful AUC monitoring is reasonable. Why: efficacy and toxicity must be balanced.

Case 4: Positive blood PCR panel: Enterococcus faecalis with vanA negative; urine culture pending; patient febrile, no hardware.

  • Therapy? Ampicillin if susceptible; avoid vancomycin default. Why: beta-lactams are more bactericidal for E. faecalis and align with stewardship.

Exam-day strategy and mindset

  • Work the stem: Identify source, severity, risk factors (prior antibiotics, devices, travel), and local resistance clues.
  • Eliminate unsafe or non-steward options: Redundant double-coverage, unnecessary prolonged durations, broad agents without indication.
  • Time management: Keep a steady pace; flag time sinks. Many questions are solvable in under a minute when you apply your frameworks.
  • When torn between two: Choose the option that treats the source effectively with the narrowest appropriate spectrum and best PK/PD at that site.

Common pitfalls to avoid

  • Treating colonization (e.g., positive urine culture without symptoms).
  • Continuing broad-spectrum therapy after negative cultures and clinical improvement.
  • Using daptomycin for pneumonia or nitrofurantoin for pyelonephritis.
  • Ignoring AmpC/ESBL risks in Enterobacterales when selecting cephalosporins.
  • Under-dosing in obesity or augmented renal clearance; forgetting extended infusions.
  • Skipping 48–72-hour antibiotic “time-outs.”

Rapid recall: bug–drug matches that show up

  • MRSA: vancomycin (AUC), daptomycin (not for pneumonia), linezolid, ceftaroline.
  • Pseudomonas: piperacillin-tazobactam, cefepime, ceftazidime, meropenem/imipenem; refractory: ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam; cefiderocol for select DTR cases.
  • ESBL: carbapenems preferred for serious infections; consider oral step-down if stable and susceptible.
  • Anaerobes: metronidazole, beta-lactam/beta-lactamase inhibitors, carbapenems; moxifloxacin is variable.
  • Atypicals: azithromycin, doxycycline, fluoroquinolones.

Your last two weeks: how to spend them

  • Drill durations, IV-to-PO criteria, and de-escalation moves until automatic.
  • Rehearse PK/PD: vancomycin AUC logic, extended-infusion beta-lactams, aminoglycoside peaks/troughs.
  • Review resistance maps: ESBL vs AmpC vs CRE agent choices.
  • Practice 20–30 mixed questions daily. Focus on why each wrong answer is wrong.

Final checklist

  • Frameworks ready: four moments, empiric-to-targeted pathway, duration rules, IV-to-PO criteria.
  • PK/PD confident: dosing in renal failure, CRRT, obesity; AUC-based vancomycin; extended infusions.
  • Resistance savvy: ESBL/AmpC/CRE distinctions; MRSA lung vs bloodstream choices; DTR Pseudomonas strategies.
  • Stewardship metrics: DOT, C. difficile rates, de-escalation and time-to-narrow, audit and feedback.
  • Communication: how to persuade teams to shorten durations, de-escalate, or switch to oral without burning bridges.

Passing BCIDP in 2026 comes from doing what great ID pharmacists do daily: get the diagnosis right, match the drug to the bug and the patient, use the shortest effective course, and lead with stewardship. Build those habits during prep. On exam day, apply them with calm and consistency. You will think like an ID steward, and the score will follow.

Leave a Comment